🔗 Share this article

While the US proceeds with historic adjustments to its vaccination guidelines, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by expressing skepticism about COVID-19 vaccines in the global health crisis and has focused upon possible deaths following Covid immunization in her recent tenure at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Schedule

Agency leaders had intended to unveil major revisions to the childhood vaccination calendar in December, aligning the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US out of alignment with many the world with little proof for benefit. This reveal has been delayed until the coming year.

Instead of the top vaccines chief, Dr. Høeg is listed to speak at the meeting. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth person to lead the office this year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the drug and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a greater focus upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for halting certain pediatric immunization guidelines in the US so as to align more in line with the Danish model, a country with nationalized medicine and a citizenry roughly the population of Wisconsin’s.

To date public appearances, she has kept her attention on vaccines – usually the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Expertise

The appointee has little discernible background in pharmaceutical research, approval processes or administrative roles, which has been standard for past directors of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She is not versed in leading a major agency. She lacks background in pharmaceutical oversight.”

Previous heads of the center would “grasp regulatory frameworks and the research of drug development”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that previous people who led CBER have had.”

CDER has an enormous range of responsibilities at the FDA, she emphasized.

“Everybody just zeroes in on the new drug program, but the off-patent medication office clears numerous generic medications. There’s a biosimilars program, OTC medication office and more, and each of these have to be looked after,” Dr. Woodcock explained. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial leadership component to the job, which supervises over 5,000 employees. “It’s a enormous leadership role, if you do it right,” the former official added.

Response and Disputed Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this appointment signifies more teamwork among agency officials on vaccines, a press secretary stated that the “inquiries rely on incorrect presumptions”.

“Her experience aligns with the duties of her role,” the representative said, noting the time Dr. Høeg spent counseling the agency head on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the agency head's new priority voucher program, a contentious one-day therapy clearance system that apparently worried her predecessors. “How are these therapies being picked for this fast-track system? Who takes the calls?” Dr. Howard said. “There is a lot of lack of transparency going on at the FDA right now.”

Broadly speaking, he remarked, “the agency looks to be trending towards less stringent oversight of pharmaceuticals, with the exception of immunizations.”

Established Track Record on Vaccines

With vaccines, Høeg has a clearer, if concerning, past, critics have noted. She released a research paper using unconfirmed public submissions to determine the incidence of heart inflammation after Covid vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccines are pose a greater threat than they are.

Included in her “policy goals” for the incoming federal leadership included altering regulations for recently developed shots and discontinuing “non-essential” immunizations, she said after the election on a online show. At the FDA, Dr. Høeg has allegedly suggested barring adolescent males from obtaining COVID-19 vaccines.

“She’s an thorough true believer who starts off with her conclusions and works backwards to fit the science in a extremely disingenuous, fraudulent manner,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|